Skip to main content
. Author manuscript; available in PMC: 2024 Dec 1.
Published in final edited form as: Blood Coagul Fibrinolysis. 2023 Oct 27;34(8):499–507. doi: 10.1097/MBC.0000000000001258

Table 2:

Reason for study medication discontinuation: 9 (24.3%) patients required study drug discontinuation: 5 (27.8%) patients in the Control group versus vs 4 (21.1%) in the Experimental group, p=0.71.

group Reason for discontinuation Hospital day drug was discontinued VTE
Control Attending discretion 4 No
Control Pulmonary embolism 3 Yes
Control Received ASA per attending discretion 7 No
Control Platelet count <50,000/mcl 3 Yes
Control Suspicion of gastric bleeding, not confirmed 19 No
Experimental Suspicion of pulmonary embolism, not confirmed 2 No
Experimental Platelet count <50,000/mcl 1 No
Experimental Pharmacy miscommunication 2 No
Experimental Pharmacy miscommunication 4 No